|Bid||6.21 x 0|
|Ask||6.24 x 0|
|Day's Range||6.11 - 6.44|
|52 Week Range||4.76 - 20.96|
|Beta (3Y Monthly)||3.53|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By the end of September, HEXO was one of the few cannabis companies to have delivered positive returns in 2019. However, this month has been tough.
Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...
Cannabis stocks see dark clouds looming. The week ending on October 11 was disastrous for the sector. Hexo stock fell after it withdrew its fiscal 2020 outlook.
(APHA) will be the first marijuana company to report quarterly earnings since last week’s cannabis stock selloff. Its fiscal first-quarter earnings announcement is scheduled for Tuesday, after the market closes. Aphria stock (ticker: APHA) is down about 17% so far this year through Friday’s close at $4.71, while the S&P 500 index has risen 19%.
(Bloomberg) -- A year ago, investors were positively exuberant about pot’s potential. Now they’re dejected.This Thursday marks the one-year anniversary of Canada’s legalization of recreational cannabis and most of the sector’s stocks have never regained the peaks they hit shortly before that date.Instead, after a brief reprieve in the first quarter of this year, they’ve been on a consistent downward slide, with the Horizons Marijuana Life Sciences Index ETF now down 56% from its recent high on March 19.Last week was a particularly brutal one, as Hexo Corp. joined the ranks of pot companies that have lowered earnings expectations. Its stock tumbled 23% Thursday and a further 11% Friday after the company said its fourth-quarter revenue will come in well below analyst expectations and withdrew its forecast for fiscal 2020.That hammered the entire sector, with the Horizons fund -- which trades as HMMJ in Toronto -- hitting lows not seen since 2017.Expectations for the coming earnings season may still be too rosy, according to Jefferies analyst Ryan Tomkins.“Into the next quarter we continue to think consensus may be expecting too much sequentially from names in a market where growth is not significant (yet), some capacity is being earmarked for extraction, and costs are increasing as preparation for derivatives ramps up,” Tomkins said in a note.We’ll get a better sense of how the Canadian market is shaping up when Aphria Inc. reports results for the quarter ended Aug. 31 on Tuesday. The Leamington, Ontario-based producer pulled off a rare feat in its last quarter when it became the first large cannabis company to report a profit, with a 75% increase in revenue, sending its shares up 40% in one day.CIBC analyst John Zamparo believes Aphria’s good fortune reversed in the latest quarter, and expects it to report a loss and a slight sequential decline in revenue to C$126 million.“Licensing delays, a protracted retail rollout in Canada’s most populous provinces and slow replenishment by provincial boards have hurt demand, profitability and growth,” he wrote. Despite the weakness, he expects Aphria to reiterate its fiscal 2020 guidance of C$650 million to C$700 million in revenue and C$88 million to C$95 million in adjusted earnings before interest, taxes, depreciation and amortization.Tomkins at Jefferies thinks those numbers are “no longer possible” and expects Aphria to reduce them. However, he remains bullish on the stock, citing its strong global outlook, compelling valuation and the possibility for “a material move into the U.S. in the current year.”For a more comprehensive look at the state of Canada’s cannabis market one year in, watch for our coverage on Tuesday.Upcoming Events This WeekTUESDAY 10/15Aphria Inc. reports earnings pre-marketThe Conference Board of Canada hosts Cannabis at Work: One Year Later in Toronto, releasing new research on the impact of pot legalization on the workplaceValens GroWorks Corp. releases earnings post-marketWEDNESDAY 10/16Canada 2020 hosts the 2020 Cannabis Public Policy Conference through Oct. 17Last Week’s Top StoriesHexo Falls 20% as Pot Firm Sees Weak Sales, Drops 2020 GuidancePot Stocks Fall to 2017 Lows as Hexo Latest to Lower OutlookPot Stock Weakness Scuttles MedMen’s Acquisition of PharmaCannIsraeli Pot Firm Breath of Life Delays IPO Until Market ImprovesAs Canada Pot Gets Cheaper, Black Market Still Offers Best DealsGreen Organic Eyes Pot Bonds, Private Debt to Fund PremisesColombia, Notorious for Illicit Cocaine Trade, Embraces CannabisTo contact the reporter on this story: Kristine Owram in Toronto at email@example.comTo contact the editors responsible for this story: Brad Olesen at firstname.lastname@example.org, Jeremy R. Cooke, Courtney DentchFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Marijuana stocks were mixed Friday, even as a Jefferies analyst made deep cuts to price targets on Aurora Cannabis and Canopy Growth.
Cannabis stocks surrendered some of their early gains Friday, as the concerns about a lack of profits in the sector that sparked a massive re-rating of risk this week persisted, putting the sector on track for double-digits losses on the week.
Aphria (NYSE:APHA) shareholders continued to be disappointed as the APHA stock price drops. Despite this disappointment, no one is talking abut one piece of potentially bearish news -- and that should concern investors.Source: Shutterstock Aleafia Health (OTCMKTS:ALEAF) is a vertically integrated cannabis health and wellness company with a large presence in Canada. It produces cannabis-infused oils and capsules and it operates 25 medical clinics and education centers in Canada.So what is this bearish news? In September of last year, Aphria and Emblem Cannabis, a wholly owned subsidiary of Aleafia, came to an agreement that Aphria was to supply up to 175,000 kilograms of cannabis to Emblem. Had all gone according to plan, the five-year agreement should have started in May 2019.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOn Tuesday Aleafia said that it was terminating this agreement. This clearly was not an amicable breakup. It its statement, Aleafia attributed its decision to "Aphria's failure to meet its supply obligations under the supply agreement." A Contentious RelationshipWhen a company makes a statement like this without trying to put any spin on it, it is usually a sign of a contentious relationship. For example, Aleafia could have used more diplomatic language and said something along the lines of "after careful consideration both companies have mutually decided that it was in their best interest to end the agreement."Aleafia's statement clearly puts a negative light on APHA. Aleafia also assured shareholders that this termination of the agreement would not have any material effect on its operations.What should concern Aphria's shareholders, in my opinion, is its response to the announcement. It did not offer any explanation or try to fight back in any way. In response the company said "We are disappointed that Aleafia has chosen to terminate its Agreement with Aphria Inc. The Company had every intention of fulfilling its obligations under the Agreement."So … what happened? Why couldn't Aphria keep up its side of the agreement? Was it due to logistics or operational issues? Was it due to the fact that Aphria isn't growing enough to meet the demand? A Closer Look at Aphria StockThe ambiguity and lack of explanation in this statement would concern me if I was a shareholder. Aphria's most recent investor presentation stated that the company's annual production capacity of its combined facilities is 255,000 kilograms. If the agreement with Aleafia was for up to 175,000 kilograms over five years, that could be up to 35,000 kilograms a year -- which is more than 10% of the total capacity.Will Aphria have similar problems supplying other companies? It next reports earnings on Oct. 15. This will probably be a topic of discussion on the earnings call. If there isn't more clarity on why Aleafia terminated the agreement, it could be a very bearish signal for APHA.APHA stock is currently testing -- and possible breaking support -- around the $5 level. There was support at this level in August and early October.At the time of this writing Mark Putrino did not have any holdings in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Super Boring Stocks to Buy With Super Safe Returns * 10 Winning Stocks to Buy and Stick With for the Long Haul * Don't Give Up on These 4 Cannabis Stocks The post Aleafia's Announcement Should Concern Aphria Stock Investors appeared first on InvestorPlace.
The cannabis sector continued its downward movement in the week that ended on October 10, with ETFs and prominent cannabis players falling.
As of Thursday, Canopy Growth has lost 10.5% of its stock value in October. As of the same day, the company has lost 25.8% of its stock value YTD.
On Thursday, Canopy Growth announced that Constellation’s CFO David Klein will be the new chairman of its board effective immediately.
Technical analysis has a bad reputation. This isn't surprising because most of the technical analysis of marijuana stocks that I see is not very good. Some is downright terrible.Even worse, some analysts are proponents of bizarre techniques like Gann Theory or Elliot Waves. These methods are like the Loch Ness Monster or UFOs. They may be fun to talk about, but they are not real.What is real is the fact that in financial markets, certain levels are more important than others. These levels have more supply and demand at them. In addition, in financial markets prices are always doing one of three things -- going up, going down or staying the same. When understood and applied correctly, technical analysis should help you identify these levels and trends. This can lead to low-risk trading ideas.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Super Boring Stocks to Buy With Super Safe Returns After becoming the most oversold that they have ever been two weeks ago, many of the larger cannabis stocks have broken their downtrends and have been consolidating or trading sideways. It is too soon to tell whether or not they will turn around, but we have not seen the capitulation volumes that come with significant bottoms. This means there is a chance that they could start to trend lower again. Marijuana Stocks With Big Technical Levels: Aphria (APHA)Aphria (NYSE:APHA) manufactures and sells medical cannabis in Canada and internationally. It currently has a market cap of about $1.3 billion.APHA stock went into a free-fall after it broke support around the $6 level. This level was the low in mid- and late August.After becoming oversold, it found some support around the $5 level. There is support at this level because it is where the low was in early August. It has now broken its downtrend and is consolidating above $5.The term oversold refers to momentum. Momentum is a measure of where the stock is now versus where it was X many days ago. If the average of this measurement gets to an extreme on the downside, it would be considered to be oversold.This action illustrates an important dynamic about markets. When they are oversold and get to important support, they tend to rebound. When they get to important support and are not oversold, they tend to break the level. Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems and hemp-related food products.ACB stock was in a freefall, but after becoming oversold it has broken its downtrend and is consolidating.It found support right at the $4 level. This illustrates how nice, round levels are important psychologically. There is really no logical reason for doing so, but investors like to place their buy and sell orders at numbers like $10 or $20.If ACB turns around and rallies, there is a good chance that it will hit resistance around the $5.50 level. This is because it was a support level in August in addition to being important psychologically. * 10 Best Cloud Growth Stocks Right Now Few investors think about this, but why would a level that was support become resistance? Consider the following. Those investors who bought the stock at the support level are losing money once it goes lower. They do not want to sell it for a loss, so they tell themselves that if it rallies back up to tbreakeven, they will sell it to get out at breakeven. The large amount of sell orders for supply of the stock at that level creates resistance. Canopy Growth Corp (CGC)Canopy Growth Corp (NYSE:CGC) produces, distributes and sells cannabis in Canada. It has a market cap of $7.9 billion.CGC stock has broken support around the $23 level. There was support at this level because it is where the recent lows were in late August and early September. It has now become a resistance level.This is an illustration of how levels that were support become resistance. Investors who bought it at the level are losing money when the support breaks and the stock goes lower. They don't want to take a loss and decide that if it rallies back to the level they will get out of it at breakeven.In addition to this, the short-sellers are making money when the stock goes lower. They believe they made the correct decision and tell themselves that if the stock rallies back, they will short more and add to their positions.Added to this are professional traders seeking to profit off of a clearly defined level, and you can see that there are three groups of investors who want to sell stock at the level. This supply of stock is what creates resistance. Cronos Group (CRON)Cronos Group (NASDAQ:CRON) produces and sells cannabis in Canada and Germany. Its current market cap is about $2.7 billion.CRON stock recently broke its downtrend line and has been consolidating. If you want to be successful, you need to understand the concept of trends.When markets are going higher, the forces of demand are in control of the market. When they are headed lower, the forces of supply are in control. When prices aren't moving or are trading sideways, the forces of supply and demand are roughly equal.The break of a trendline can illustrate that the leadership of the market is changing or at the very least equalizing. In the case here, the break of the blue downtrend line shows that the forces of demand have for the time being, become equal with the forces of supply. * 10 Great Biotech Stocks to Buy in Q4 Of course, drawing trendlines is an art and not a science. But with some practice and an understanding of just what it is that they are supposed to show, they can help you make investment decisions. Hexo (HEXO)Hexo (NYSE:HEXO) produces, markets and sells cannabis. The current market cap is about $945 million, according to Zacks.HEXO stock may be breaking support around the $3.90 level. This level was support at the end of July, the end of August, and then again over the past two weeks. It will probably become a resistance level if it breaks.This chart illustrates how market bottoms are typically more volatile than market tops. This is due to human emotions. Stocks are bought due to hope. Stocks are sold due to fear. Fear is a much more powerful emotion than hope.When markets are forming bottoms, like they did in July, August, and now, sellers are afraid that the stock will continue to drop. Because of this, they sell aggressively without caring too much about the price. This dynamic is what creates the volatility. Medicine Man Technologies (MDCL)Medicine Man Technologies (OTCMKTS:MDCL) provides cultivation consulting services to cannabis growers. The current market cap is about $130 million. MDCL failed at resistance after becoming overbought and is now trending lower.The levels around $3.90 were the top in April, and then again in May and June. This is the reason why there is resistance at this level.Overbought refers to the momentum of the stock. Momentum is where the price is today versus where it was X many days ago. When this number reaches an extreme to the upside, it is considered to be overbought.This is an important dynamic to understand about markets. When markets are overbought and get to important resistance, they tend to selloff, as is the case here. * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? When markets are not oversold or overbought and get to important support or resistance levels, they tend to consolidate before resuming the trend. Tilray (TLRY)Tilray (NASDAQ:TLRY) engages in the research, cultivation, processing and sale of cannabis. Its current market capitalization is $2.8 billion.TLRY stock broke support around the $25 level. There was support at this level because it is where the recent low was in early September. It has become a resistance level. The recent downtrend has been broken and the stock is trading sideways.Longer-term, if the TLRY continues to drop there will probably be some meaningful support around the $22 level. This is because this is where the stock hit the market last summer when it went public.This is because various stake holders, such as investment bankers who brought the company public, early investors, and the management do not want it to break that level. This may cause them to become buyers which would create support. Cannabis Sector Momentum Last week, cannabis stocks and other equities became the most oversold that they have ever been. This means that the stocks are trading at levels that are significantly below their recent averages. Typically, when stocks are this oversold they then to rally.However, there is an interesting dynamic occurring here. Usually when stocks or sectors are this oversold, they are capitulating.Capitulation mean that the sellers want to aggressively sell their stock. They do not care about the price. They just want to get out of the position because they are are tired of watching the price drop. These dynamics usually cause large amounts of volume to trade while the stock makes a large move lower. * Don't Give Up on These 4 Cannabis Stocks In the situation here, despite being historically oversold, there has not been a significant increase in the average trading volume. This could be an indication that the sector is not yet ready to turn around and it will continue to trend lower after the current consolidation that is occurring. CannTrust (CTST)If you follow cannabis stocks, you are probably familiar with the CannTrust (NYSE:CTST) story. If you aren't, you should be, because I think we will soon be hearing about similar situations at other cannabis companies.CannTrust once had a market cap of more than $1 billion and was considered an industry leader. Then it got caught growing cannabis in unlicensed grow rooms after a disgruntled ex-employee tipped of the authorities. And as is typically the case nowadays, the management of the company discussed their illegal activities in detailed emails that the have been seized.This led to the CEO being fired, the president resigning and the stock crashing.Now it turns out that CannTrust was also using illegal seeds to grow in legal grow rooms. This resulted in illegal cannabis being sold in the legal markets -- though a CannTrust spokesperson disputed the latter part.It should come as no surprise that Health Canada has suspended its license. The company will also have to buy back and probably destroy the cannabis that it has sold, among other steps. I am not so sure that CannTrust, now better known as "Can't Trust," will be around for much longer.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Super Boring Stocks to Buy With Super Safe Returns * 10 Winning Stocks to Buy and Stick With for the Long Haul * Don't Give Up on These 4 Cannabis Stocks The post 9 Critical Things to Watch in Marijuana Stocks appeared first on InvestorPlace.
Hexo (HEXO) is having a hard time. As of 11:43 AM ET today, the stock has fallen 24%. The company announced that it's withdrawing its fiscal 2020 outlook.
Aphria is scheduled to report its earnings for the first quarter of fiscal 2020 on October 15. September wasn’t a good month for the cannabis industry.
The US markets rose on optimism surrounding US-China trade talks. However, weakness in the cannabis sector led the cannabis ETFs trading in the red.
Yesterday, Aleafia announced the termination of Aphria’s supply agreement for wholesale cannabis with wholly-owned Aleafia subsidiary Emblem Cannabis.
Cannabis stocks trade lower Tuesday, weighed down by losses in the broader market after the U.S. blacklisted Chinese tech companies, with the collapse of a merger and ending of a supply agreement adding to the gloom.
Aleafia Health says marijuana grower Aphria failed to keep up its end of a supply agreement, and now it is moving to terminate the deal.
Canadian cannabis company Aleafia will scrap a wholesale supply agreement with Aphria, and Aurora Cannabis launched a line of cannabis-infused dissolve strips in Canada's medical market.
Aurora Cannabis and Aphria are down 17.14% and 5.27%, respectively, year-to-date. These performances are mostly in line with the cannabis sector downtrend.
Maine legalized recreational marijuana in 2016. It's now confirmed the state could see preferred marijuana products hitting the market by March 2020.
Aleafia Health Inc. (TSX: ALEF) (OTC: ALEAF) said Tuesday that it is terminating a cannabis supply agreement between Aphria (TSX: APHA) (NYSE: APHA) and Aleafia subsidiary Emblem Corp. Per the agreement, Aphria was set to provide Aleafia’s subsidiary with 175,000 kg equivalents of cannabis products, but Alefia said Aprhia has failed to do so. "Following Aphria’s failure to meet its supply obligations under the supply agreement, Emblem has exercised its contractual right to terminate the supply agreement in accordance with its terms.